Syros Announces Closing of Concurrent Public Offerings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Syros Pharmaceuticals (SYRS) PT Lowered to $24 at Piper Jaffray
April 10, 2019 9:19 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Syros Pharmaceuticals (NASDAQ: SYRS) to $24.00 (from $28.00) while maintaining a Overweight rating. Syros recently raised gross proceeds of $70 million, bringing estimated pro forma cash to ~$165 million.
Syros is developing potentially best-in-class CDK7 inhibitors.... More
